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INTRODUCTION
The effects of estrogen and progesterone are mediated by 
specific transmembrane receptors. Estrogen receptor (ER) and 
progesterone receptor (PR) are well-known prognostic factors 
in endocrine organ cancers. The clinical relevance of these 
receptors has been clearly established for endometrial and 
breast cancers [1]. There is currently a wide range of theories 
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Objective: To examine the patterns of estrogen receptor (ER) and progesterone receptor (PR) expression in borderline ovarian 
tumors (BOTs) and ovarian carcinomas. We also assessed the disease-free survival (DFS) and overall survival (OS) in women with 
ovarian carcinoma, in relation to ER and/or PR expression. 
Methods: We examined ER/PR expression in 38 BOTs and 172 ovarian carcinomas removed from patients treated at the State 
University of Campinas-UNICAMP (Brazil), from 1993 to 2008 and followed for up to 60 months using tissue microarray-based 
immunohistochemistry. 
Results: Twenty-eight (73.7%) mucinous and 10 (26.3%) serous BOTs were included. Ovarian carcinomas consisted mainly of 
79 (46.0%) serous, 44 (25.5%) mucinous, 17 (9.8%) endometrioid, 10 (5.8%) clear-cell types. There was no significant difference 
of the ER/PR expression between BOT and ovarian carcinoma (p=0.55 for ER alone, 0.90 for PR alone, and 0.12 for combined 
expression). The level of ER/PR expression in BOTs was significantly higher in serous than in mucinous tumors (p<0.01). 
In carcinomas, ER/PR was higher in serous tumors than in mucinous (p<0.01) and clear cell tumors (p=0.02), and higher 
in endometrioid tumors than in mucinous tumors (p<0.01). DFS was affected neither by the clinical characteristics nor by 
combined steroid receptor status. OS was found to be significantly worse (p<0.01) only in women with stages II-IV tumors and 
those with residual disease after surgery (p<0.01). 
Conclusion: Overall, serous and endometrioid tumors were predominantly ER/PR positive, whereas mucinous and clear-cell 
tumors were preponderantly ER/PR negative. DFS and OS were not affected by ER/PR expression.
Keywords: Borderline ovarian tumor, Estrogen receptor, Immunohistochemistry, Ovarian carcinoma, Progesterone receptor, 
Tissue microarray
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about ovarian carcinogenesis. However, recent evidence sug-
gests that steroid hormonal stimulation may be implicated in 
the development and prognosis of ovarian malignancies. Thus, 
the study of steroid receptors in the ovary takes on an added 
importance [2,3].
Estrogens are main regulators of growth and differentiation 
in ovarian cells. Recent laboratory and preclinical data suggest 
that estrogens may exert a mutagenic effect on normal epithe-
lial ovarian cells. In contrast, progesterone may offer protection 
against the mutagenic effects of estrogens by blocking cell 
growth and inducing cell differentiation and apoptosis. Studies 
addressing the potential carcinogenic or anticarcinogenic 
effects of these steroids generally examine mRNA transcription 
and ER/PR protein expression [4,5]. However, multiple techni-
cal dissimilarities between studies, in addition to the small 
samples evaluated in many reports precluded any conclusive 
analysis of the role of steroid receptors in the ovary. 
Some authors have advocated that ER and/or PR expression 
may predict the survival of women with ovarian carcinomas 
[1-3,6-16], whereas several other reports have failed to detect 
such an association [17-19]. Attempts to define typical steroid 
receptor profiles among ovarian histologic types have been 
made. Reasons for failure in these attempts and for the dif-
ferent results obtained in previous studies can be attributed 
to the dissimilar techniques used to analyze steroid receptor 
expression and a low level of agreement between histologic 
evaluations.
Inconclusive data from previously published studies on ovar-
ian cancer prognosis in relation to steroid hormone expression, 
prompted us to investigate the large dataset of ovarian 
carcinomas with a long-term follow-up period in our service. 
We evaluated the patterns of ER/PR expression between differ-
ent histologic types of epithelial ovarian neoplasms, borderline 
ovarian tumors (BOTs) and carcinomas. The disease-free 
survival (DFS) and overall survival (OS) of women diagnosed 
with carcinomas in relation to steroid receptor expression were 
also studied.
MATERIALS AND METHODS
1. Patient selection
For this retrospective cohort study, we selected women 
undergoing surgical treatment for BOTs or ovarian carcinoma 
from 1993 to 2008 at the State University of Campinas-
UNICAMP, São Paulo, Brazil. All study participants had 
surgeries classified as surgical staging (disease restricted to 
the ovaries) or cytoreductive surgery (advanced disease). The 
sample included women undergoing complete or incomplete 
staging and optimal or suboptimal cytoreduction. Follow-
up data were retrieved up until December 2010. Excluded 
from the study were all women 1) undergoing neoadjuvant 
chemotherapy, 2) whose paraffin blocks were unavailable 
or inadequate, and 3) with other synchronous or metastatic 
tumors to the ovary. We assessed pathological and clinical 
(including follow-up) data from 38 BOTs and 172 ovarian 
carcinomas cases, totaling 210 women. Clinical data were col-
lected from patient medical records. Patient age, menopausal 
status, tumor histologic type and grade, disease stage [20], 
and surgical outcomes (optimal or suboptimal surgery) were 
recorded. 
In our institution, surgical staging of BOT included peritoneal 
washings, total abdominal hysterectomy, bilateral salpingo-
oophorectomy with omentectomy, as well as pelvic and ab-
dominal peritoneal biopsies. In selected patients, who desired 
childbearing and had BOT or stage I carcinomas (restricted to 
the ovary), unilateral salpingo-oophorectomy (fertility-sparing 
surgery) was performed. For ovarian carcinoma, surgical 
staging included peritoneal washings, total abdominal hys-
terectomy, bilateral salpingo-oophorectomy, omentectomy, 
pelvic and paraaortic lymph node biopsies with pelvic and 
abdominal peritoneal biopsies. Cytologic examination of 
ascitic fluid or peritoneal washings was performed in all cases. 
For advanced disease in BOTs or ovarian carcinomas, surgery 
included total abdominal hysterectomy, bilateral salpingo-
oophorectomy with omentectomy and debulking to remove 
as much of gross tumor as possible. Cytoreduction was 
deemed “optimal” when residual implants measuring less 
than 1 cm were left. The presence of ascites was evaluated 
either by ultrasound or computed tomography (CT) scan or 
intraoperative examination. Histologic classification of ovarian 
tumors was performed, following World Health Organization 
(WHO) and International Federation of Gynecology and Ob-
stetrics (FIGO) recommendations [20,21]. Patients underwent 
chemotherapy regimens with carboplatin, receiving either 
paclitaxel or cyclophosphamide, according to service protocol.
This study was approved by the Research Ethics Commit-
tee of the State University of Campinas (protocol number 
1086/2009).
2. Specimens
Samples for tissue microarray (TMA) were obtained from 
the original paraffin blocks. All hematoxylin and eosin (H&E) 
stained slides were reviewed by an experienced pathologist to 
select the paraffin blocks most suitable for TMA sampling, i.e., 
those having unequivocal areas of BOT or ovarian carcinoma. 
Two areas of interest corresponding to the most representa-
tive areas of the tumor were marked and selected from each 
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case for TMA construction. These marks guided the 1.0 mm 
cylindrical core of the paraffin blocks, which was performed 
using a TMA instrument (Beecher Instruments Microarray 
Technology, Silver Springs, CA, USA). TMA processing and 
analysis were performed, according to standard protocols that 
have been fully validated in ovarian pathology [22].
3. Assay methods
Immunohistochemistry (IHC): Four-micrometer TMA sections 
were deparaffinized with xylene and dehydrated in graded 
alcohols, according to normal protocols. For antigen retrieval, 
a commercially available pressure cooker (Pascal, Dako, 
Carpenteria, CA, USA) was used, immersing the slides in citrate 
Fig. 1. Representative immunohisto che-
mical nuclear staining of progesterone 
receptor (PR) and estrogen receptor (ER). 
(Peroxidase). (A) PR: zero score (negative). 
(B) PR: 1%-10% cells stained/moderate 
intensity (final scoring 2+2=4). (C) PR: 35%-
75% cells stained/strong intensity (final 
scoring 4+3=7). (D) PR: ≥75% cells stained/
strong intensity (final scoring 5+3=8). (E) 
ER: zero score (negative). (F) ER: 1%-10% 
cells stained/moderate intensity (final 
scoring 2+2=4). (G) ER: 35%-75% cells 
stained/strong intensity (final scoring 
4+3=7). (H) ER: ≥75% cells stained/strong 
intensity (final scoring 5+3=8). Peroxidase 
(A, B) ×40, (C, D) ×100,  (E, H) ×400. 
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buffer solution, pH 6.0 for 30 minutes. The slides were allowed 
to air-dry at room temperature and then washed in distilled 
water. The sections were incubated in a humid chamber with 
the specific primary antibodies at 4oC overnight. We assessed 
the ER α subtype (ER, clone 1D5; Dako) [2,4]. Only the PR-A 
subtype is appropriate for IHC detection (PR, clone PgR 636; 
Dako) [2,23]. Internal and external, positive and negative 
controls were used to validate the reactions. Subsequently, 
the slides were washed in phosphate buffered saline [PBS], 
pH 7.4, incubated in ADVANCE HRP Detection System (Dako) 
at 37oC for 1 hour, and washed in PBS. DAB chromogen 
substrate (3-diaminobenzidine, Sigma-Aldrich, St. Louis, MO, 
USA) was applied, at a proportion of 0.06 g to 100 mL of PBS, 
500 µL hydrogen 3% peroxide and 1 mL dimethyl sulfoxide 
at 37oC for 5 minutes. The slides were washed with water and 
counterstained with Harris’ haematoxylin for 30 to 60 seconds, 
dehydrated, cleared and mounted on Entellan resin (Merck, 
Darmstadt, Germany). Internal and external, positive and 
negative controls were used for validation of the reactions [22].
4. Evaluation and interpretation of IHC
A single pathologist, who was blinded to the clinical and 
pathological data, scored the samples. Two TMA cores from 
each tumor were used for each marker, i.e., each tumor was 
assessed twice. If scores differed in both areas, the stronger 
staining was considered. Nuclear staining of ER and PR were 
recorded, as follows: 0, negative; 1, less than 1% stained nuclei; 
2, 1% to 10% stained nuclei; 3, 10% to 35% stained nuclei; 4, 
35% to 75% stained nuclei; 5, ≥75% stained nuclei. Nuclear 
staining intensity was also categorized as: 1, weak; 2, moder-
ate; 3, strong. The final score was the sum of the percentage 
score of stained nuclei (ranging from 0-5) plus intensity score 
of the reaction (1-3). Therefore, the possible final scores 
were 0 (no staining), 2 (less than 1% and weak), 3, 4, 5, 6, 7, 
and 8. For statistical purposes, the final IHC ER/PR status was 
considered positive, when the score was ≥4 (Fig. 1).
5. Statistical analysis
Statistical analyses were performed by using the R Environ-
ment [24] statistical software package, with 95% confidence 
intervals (CI). Chi-square tests (and Fisher’s exact tests, when 
required) were used to compare the clinical characteristics 
of women with BOT or ovarian carcinoma, and to evaluate 
steroid hormone expression among the histologic samples. A 
multivariate generalized linear model using binomial distribu-
tion (logistic regression) was fit to evaluate the combined ER/
PR status of ovarian carcinomas, related to clinical and patho-
logical features. We obtained a median follow-up period of 42 
months (range, 17 to 60 months; 50% central-range). Sample 
size calculations for the survival models resulted in a sample 
requiring 105 subjects with complete follow-up. We used the 
multivariate Cox proportional hazards analysis to calculate the 
Table 1. Key features of women with BOT and ovarian carcinoma
Clinical characteristic BOT Carcinomas p-value 
Total 38 (18.0) 172 (82.0)
Age (yr) <0.01
    <50 27 (72.2) 59 (34.3)
    ≥50 11 (27.8) 113 (65.7)
Menopausal status <0.01
    Pre 24 (63.9) 48 (27.9)
    Post 14 (36.1) 124 (72.1)
Histologic type NC
    Serous 10 (26.3) 79 (46.0)
    Mucinous 28 (73.7) 44 (25.5)
    Endometrioid - 17 (9.8)
    Mixed - 16 (9.3)
    Clear cell - 10 (5.8)
    Adenocarcinoma - 4 (2.4)
    Transitional cells - 2 (1.2)
Stage NC
    I 35 (92.1) 61 (35.4)
    II 3 (7.9) 11 (6.4)
    III - 90 (52.0)
    IV - 10 (6.2)
Histologic grade 0.12
    0 38 (100) -
    1 - 45 (26.0)
    2 - 64 (37.6)
    3 - 63 (36.4)
ER 0.55
    Negative 27 (71.1) 111 (64.5)
    Positive 11 (28.9) 61 (35.5)
PR 0.90
    Negative 28 (73.7) 125 (73.0)
    Positive 10 (26.3) 47 (27.0)
Combined receptor status 0.12
    ER-/PR- 25 (65.8) 90 (52.3)
    ER-/PR+ 2 (5.3) 21 (12.1)
    ER+/PR- 3 (7.9) 35 (20.7)
    ER+/PR+ 8 (21.1) 26 (14.9)
Values are presented as number (%). Univariate p-values calculated 
with chi-squares and Fisher’s exact tests, when appropriate.
BOT, borderline tumor; ER, estrogen receptor; NC, non-calculable 
because BOT are either serous or mucinous and restricted to stages I 
and II tumors; PR, progesterone receptor.
ER and PR receptor status in ovarian neoplasms
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hazard ratios (HR) of DFS and OS which were defined as times 
elapsed since the main surgical procedure to time of disease 
recurrence and death from ovarian cancer, respectively, in 
relation to clinical and pathological characteristics. There was 
no significant event (relapses or deaths) in women with BOTs. 
The Kaplan-Meyer representation was used to assess OS in 
relation to patterns of ER/PR expression stratified by disease 
stage (stage I vs. stages II-IV). The curves were then compared 
using the Mantel-Cox log-rank method.
RESULTS
The mean patient age was 41.3 years (standard deviation [SD], 
13.7) for BOT, and 54.7 years (SD, 12.6) for ovarian carcinomas 
(p<0.01). The BOT group consisted of 26.3% serous and 
73.7% mucinous tumors. The histologic type of most ovarian 
carcinomas (46%) was serous type, followed by mucinous type 
(25%). Approximately 10% were mixed or endometrioid types. 
The majority (58%) of ovarian carcinomas were diagnosed 
at an advanced stage (6% were already stage IV). Disease 
recurrence was detected in 4 (27%) women with stage I serous 
carcinomas and in 39 (59%) women with stage II-IV disease. 
The primary surgical procedure was considered suboptimal 
for 66 (38%) women with ovarian carcinomas. Platinum-based 
chemotherapy drugs was for 133 (76%) women (data not 
shown). Most BOT and carcinomas were ER and/or PR negative, 
while 65.8% of BOT and 52.3% of carcinomas were negative for 
both receptors. There was no significant difference in steroid 
receptor expression, when BOT was compared to ovarian 
Table 2. Comparison of ER, PR, and combined steroid receptor status according to histologic types in BOT and ovarian carcinomas 
Histologic types Serous Mucinous Endometrioid Clear cell Others* p-value
BOT 
    ER <0.01
        Negative 3 (30.0) 24 (86.0) - - -
        Positive 7 (70.0) 4 (14.0) - - -
    PR <0.01
        Negative 3 (30.0) 25 (89.3) - - -
        Positive 7 (70.0) 3 (10.7) - - -
    Combined receptor status† <0.01
        ER-/PR- 2 (20.0) 23 (82.0) - - -
        ER-/PR+ 1 (10.0) 1 (3.6) - - -
        ER+/PR- 1 (10.0) 2 (7.2) - - -
        ER+/PR+ 6 (60.0) 2 (7.2) - - -
Ovarian carcinomas
    ER <0.01‡
        Negative 38 (48.1) 41 (93.2) 6 (35.3) 10 (100.0) 16 (73.0)
        Positive 41 (51.9) 3 (6.8) 11 (64.7) 0 6 (27.0)
    PR 
        Negative 55 (69.6) 40 (90.9) 7 (41.2) 8 (80.0) 15 (68.0) p§
        Positive 24 (30.4) 4 (9.1) 10 (58.8) 2 (20.0) 7 (32.0)
    Combined receptor status 
        ER-/PR- 30 (38.0) 38 (86.4) 3 (17.6) 8 (80.0) 11 (50.0) p‖
        ER-/PR+ 8 (10.1) 3 (6.8) 3 (17.6) 2 (20.0) 5 (23.0)
        ER+/PR- 25 (31.6) 2 (4.5) 4 (23.5) 0 4 (18.0)
        ER+/PR+ 16 (20.6) 1 (2.3) 7 (41.2) 0 2 (9.0)
Values are presented as number (%). 
BOT, borderline tumor; ER, estrogen receptor; PR, progesterone receptor.
*The other group comprised 16 mixed, 4 adenocarcinomas no other specification and 2 transitional cell tumors. †Chi-squares and Fisher exact 
tests (when appropriate). ‡Mucinous vs. serous, serous vs. clear cell, and mucinous vs. endometrioid; §mucinous vs. serous (p=0.01), mucinous 
vs. endometrioid (p<0.01), and serous vs. endometrioid (p=0.03); ‖mucinous vs. serous (p<0.01), serous vs. clear cell (p=0.02), and mucinous vs. 
endometrioid (p<0.01). The other pairwise comparisons were not significant.
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carcinoma (p=0.55 for ER alone, 0.90 for PR alone and 0.12 for 
combined expression) (Table 1).
In BOT, ER and PR expression (alone or combined), was sig-
nificantly higher in serous than in mucinous tumors (p<0.01). 
In carcinomas, ER expression was significantly higher in serous 
vs. mucinous (p<0.01) and clear cell tumors (p<0.01), and in 
endometrioid vs. mucinous type (p<0.01). PR expression was 
significantly higher in serous vs. mucinous (p<0.01) and in 
endometroid vs. mucinous (p<0.01) and vs. serous (p=0.03). 
Considering both receptors, the level of expression was 
significantly higher in serous vs. mucinous (p<0.01) and clear 
cell (p=0.02) tumors. Other pairwise comparisons were non-
significant. Overall, endometrioid ovarian cancer showed the 
highest (82.4%) ER and/or PR expression among all types of 
ovarian cancer, whereas mucinous ovarian cancer showed the 
lowest (13.6%) ER and/or PR expression (Table 2).
Steroid receptor expression in ovarian carcinomas revealed 
no significant stage-related difference. The vast majority 
(>80%) of endometrioid tumors were positive for at least one 
steroid receptor, regardless of tumor stage. Seven (100%) stage 
I clear cell carcinomas were negative for both receptors. Of the 
3 cases of stage II-IV clear cell tumors, two were positive for at 
least one receptor (data not shown). In Tables 3 and 4, tumors 
with similar patterns of ER/PR expression were grouped 
together (mucinous, clear cell and others vs. serous and endo-
metrioid). In general, serous and endometrioid tumors were 
predominantly ER/PR positive, whereas mucinous and clear 
cell tumors were preponderantly ER/PR negative (OR, 4.61; 
95% CI, 2.07 to 10.25; p<0.01). Other tumor characteristics 
were not significantly associated with ER/PR status. 
Neither the epidemiological and clinical features studied, 
nor combined steroid receptor status affected DFS (Table 4). 
The probability of death was found to be significantly higher 
(HR, 4.0; 95% CI, 1.6 to 10.3; p<0.01) in women with advanced 
disease (stages II-IV), and for those with residual disease after 
surgery (suboptimal surgery) (HR, 2.12; 95% CI, 1.15 to 3.9; 
p<0.01). Survival curves for women with ER and PR negative 
tumors versus ER and/or PR positive tumors, stratified by dis-
ease stage and tumor type, revealed no significant difference 
in survival (Fig. 2).
DISCUSSION
In our study, there was no difference in ER or PR expression 
between BOT and ovarian carcinoma. However, we detected 
a significant difference in ER/PR expression among the 
histologic types of carcinomas. Most serous and endometrioid 
carcinomas were ER positive, leading us to group them 
together in subsequent analyses. Conversely, mucinous and 
Table 3.  Key epidemiological and clinical features in relation to combined ER and PR status
Clinical characteristic ER and PR negative ER and/or PR positive Odds ratio 95% confidence interval p-adjusted
Age (yr) 0.99
    <50 31 (34.4) 28 (35) Reference
    ≥50  59 (5.6) 52 (65) 1.00  0.45-2.21 
Histology <0.01
    Mucinous/clear cell/others 57 (63.3) 19 (23.2) Reference
    Serous/endometrioid 33 (36.7) 63 (76.8) 4.61  2.07-10.25 
Stage 0.93
    I 44 (48.9) 17 (20.7) Reference
    II-V 46 (51.1) 65 (79.3) 1.05  0.34-3.30 
Grade 0.16
    1 36 (40) 9 (11.1) Reference
    2-3 54 (60) 72 (88.9) 2.16  0.741-6.27 
Ascites 0.18
    No 55 (67.9) 35 (44.9) Reference
    Yes 26 (32.1) 43 (55.1) 1.80 0.76-4.30
Residual disease 0.26
    No 64 (71.1) 37 (45.1) Reference
    Yes 26 (28.9) 45 (54.9) 1.75  0.66-4.63 
ER, estrogen receptor; PR, progesterone receptor. 
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clear-cell carcinomas were ER and PR negative tumors in gen-
eral. The same tendencies were observed in BOT, although we 
recognize that the size of our BOT sample was very limited. ER 
and PR expressions, alone or combined, were not related to 
either DFS or OS in women with ovarian carcinoma.
The clinical significance of steroid receptor status for the 
prognosis of ovarian cancer is still unclear. In theory, since 
estrogen affects the development of the ovarian follicles and 
ovarian cancer cell lines, dependent on ER expression, ER 
status should be associated with a difference in survival. On 
the other hand, progesterone inhibits DNA synthesis and cell 
division, and thus it may exert a protective prognostic effect 
on women with ovarian cancer [25]. Several reports have 
shown no significant difference in survival with increasing lev-
els of PR expression [17-19] , while few reports have indicated 
that a higher ER status correlates with increased survival [7,11]. 
Other authors have reported that a higher PR status is associ-
ated with increased survival [1-3,5,8-10,12-14,16]. However, 
significant methodological dissimilarities exist between 
studies, and discrepancies in the reports may be attributed to 
these methodological issues. For instance, earlier works were 
performed using the dextran-coated charcoal (DCC) method 
[7,9,11-14,16-19]. The DCC method produced false-positive 
results if the surrounding benign tissue expressed the recep-
tor on stromal cells [2]. IHC is currently the standard for ER/PR 
detection, allowing for precise detection of the receptors in 
tissues of interest [2,22].
Our findings are in agreement with results from previous 
reports on ER/PR expression in different histologic types of 
epithelial ovarian tumors [2-5]. Taken together, previous find-
ings indicate that serous and endometrioid tumors express 
ER and/or PR. Endometrioid tumors have been reported to 
primarily express PR, whereas mucinous tumors are most 
likely to be ER and PR negative [2-5]. Restricting our literature 
search to IHC-based studies, we found that frequencies of ER 
and PR expression varied from 38% to 77% (mean, 59%) and 
from 26% to 43% (mean, 33%), respectively [1-3,5,8-10]. Using 
IHC, we found a somewhat lower prevalence of ER (35.5%) 
and PR (27%) positive ovarian carcinomas in our series. 
A few studies have suggested that PR positive status is 
Table 4.  Clinical subset analyses of overall and disease-free survival of women with ovarian carcinoma
Clinical characteristic
Overall survival Disease-free survival
HR 95% CI p-value* HR 95% CI p-value*
Age (yr) 0.90 0.40
    <50 Reference
    ≥50 1.04 0.60-1.78 0.80 0.47-1.36
Histology 0.20 0.07
    Mucinous/clear cell/others Reference
    Serous/endometrioid 0.68 0.39-1.22 0.57 0.31-1.05
Stage <0.01 0.49
    I Reference
    II-IV 4.06 1.60 -10.3 1.36 0.56-3.31
Grade 0.13 0.20
    1 Reference
    2-3 1.98 0.83-4.76 1.70 0.74-3.90
Ascites 0.82 0.67
    No Reference
    Yes 0.94 0.54-1.62 1.12 0.66-1.93
Residual disease <0.01 0.35
    No Reference
    Yes 2.12 1.15-3.91 1.32 0.74-2.34
Combined receptor status 0.17 0.51
    ER-/PR- Reference
    ER+ and/or PR+ 0.69 0.40-1.1 0.83 0.48-1.43
CI, confidence interval; ER, estrogen receptor; HR, hazard ratio; PR, progesterone receptor. 
*p-values calculated using a multivariate Cox proportional Hazards model.
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an independent prognostic factor, associated with better 
survival in multivariate analysis [3,5,8,10]. Other studies failed 
to demonstrate or only indicated a trend towards a correlation 
between PR status and a favorable survival. However, this was 
not shown to be significant, either by univariate or multivariate 
analysis [11]. It is worth mentioning that DCC-based studies 
[17-19] also found no relationship between DFS and OS and 
ER/PR status in ovarian carcinomas. Other important aspects 
were examined in those studies, e.g., the relationship between 
steroid receptor status and response to chemotherapy [19], 
surgical stage [17,19] and histologic type and grade [19], but 
all those analyses yielded negative results.
In a study of 106 cases [2], ER positive expression did not 
show any association with DFS or OS, whereas PR positive 
expression had a significantly positive influence on survival in 
univariate analysis. Both median DFS and OS in patients with 
tumors expressing PR positive were significantly longer than 
those in patients with PR-negative tumors. Of the 4 alternative 
combinations of ER positive/negative and PR positive/nega-
tive expressions, the best prognostic indicator of DFS and OS 
was found in patients with ER-/PR+ expression, compared 
to women with tumors showing any of the other 3 combina-
tions. However, there were no statistically significant differ-
ences. The effects of PR status disappeared on multivariate 
analyses, and the remaining factors associated with survival 
were disease stage and response to first-line chemotherapy. 
A recent report [10] detected that ER alone, in contrast to PR 
alone, had no prognostic value. However, those authors inves-
tigated combined ER/PR expression and found that ER-/PR+ 
tumors were particularly associated with an increased overall 
survival, compared to PR+ tumors. Using IHC, Munstedt et al. 
[10] found a positive influence of ER-/PR+ tumors on patient 
survival in both uni- and multivariate analyses. In addition, PR 
was inversely correlated with tumor stage and high degree of 
differentiation, findings that were in accordance with another 
study [8]. 
Fig. 2. Kaplan-Meier depiction of overall survival probabilities of women with (A) serous/endometrioid International Federation of Gynecology 
and Obstetrics (FIGO) stage I; (B) mucinous/clear cells/other FIGO stage I; (C) serous/endometrioid stages II-IV; and (D) mucinous/clear cells/
other FIGO stages II-IV epithelial ovarian cancer. ER, estrogen receptor; PR, progesterone receptor status.
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Although Lee et al. [8] failed to demonstrate any prognostic 
value of the ER receptor, patients with PR expression >10% 
were shown to survive longer than patients with <10% PR 
expression levels. In the Cox proportional hazards analysis, 
only disease stage and PR were significant among all the 
factors that influence survival. ER did not show any effect 
on survival. Furthermore, the combined expression of both 
markers showed no greater significance than PR alone. In a 
study by Kommoss et al. [9], ER has been shown to be of no 
significant prognostic value. Survival was significantly better in 
patients with PR positive tumors (IHC and DCC) in univariate 
analysis. According to that report, residual tumor after primary 
surgery was the only significant prognostic factor remaining 
after multivariate analysis. Contrary to all other IHC studies, 
the largest series to date [3] has detected more favorable 
outcomes for women with ER and/or PR positive carcinomas.
Our study does not support the positive influence of PR on 
prognosis, and corroborates previous findings indicating that 
ER is of no prognostic value. In our study, the only factors that 
have a significant association with survival after multivariate 
scrutiny are advanced tumor stage (II-IV) and residual disease 
after primary surgery. Both factors are well-known predictors 
of poor prognosis. 
In agreement with results from previous reports, our study 
clearly suggests that there is a need for a thorough review 
of the role of steroid receptor status in ovarian cancer. No 
definitive assumption can be made on the value of investigat-
ing ER/PR expression in either ovarian carcinomas or BOT in 
clinical practice.
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